Benefits
Wrinkle reduction 8-week RCT (Proksch 2014 PIVOTAL PMID 24401291)
Proksch 2014 (PMID 24401291, Skin Pharmacol Physiol 27(3):113-119) randomized double-blind placebo-controlled trial. 114 female participants aged 45-65 at Department of Dermatology, University Hospital of Schleswig-Holstein, Campus Kiel (Germany). VERISOL® 2.5 g/day vs placebo for 8 weeks. RESULTS: ~20% REDUCTION in periorbital wrinkle volume after 4 AND 8 weeks. 65% INCREASE in procollagen type I. 18% INCREASE in elastin levels. Foundational pivotal RCT supporting wrinkle and dermal matrix claims.
Skin elasticity 8-week dose-finding RCT (Proksch 2013)
Proksch 2013 (Skin Pharmacol Physiol original dose-finding) — randomized double-blind placebo-controlled trial in 69 women aged 35-55. Three arms: 2.5 g VERISOL®, 5.0 g VERISOL®, or placebo daily for 8 weeks. RESULTS: SKIN ELASTICITY (primary endpoint) IMPROVED in BOTH collagen hydrolysate groups vs placebo at 4 AND 8 weeks. NO statistically significant difference between 2.5 g and 5.0 g doses — establishing 2.5 g as effective standard dose. Supports long-term skin elasticity claims with 4-week post-treatment follow-up showing sustained effects in elderly subgroup.
Skin hydration recent 8-week RCT (Cosmetics 2025)
Cosmetics 2025 (Proksch E, Zdzieblik D, Oesser S 2025, Cosmetics 12(2):79, doi:10.3390/cosmetics12020079) — recent randomized double-blind placebo-controlled trial in 66 women aged 35-55. VERISOL B 2.5 g/day vs maltodextrin placebo for 8 weeks. RESULTS: Eye wrinkle volume REDUCTION (Primos Compact optical 3D), SKIN ELASTICITY improvement (Cutometer MPA 580), SKIN HYDRATION improvement (Corneometer CM 825). Confirms pivotal 2014 results with modern measurement methods. Stimulatory effect on dermal type I collagen, elastin, proteoglycan biosynthesis.
Dermal matrix synthesis stimulation (mechanistic)
VERISOL® peptides enter bloodstream as di- and tripeptides → transported to dermis → stimulate fibroblasts → SYNTHESIS of TYPE I COLLAGEN + ELASTIN + PROTEOGLYCANS. Inhibit matrix metalloproteinase (MMP)-mediated collagen degradation. Activate TGF-β1/Smad signaling pathway. Mechanism distinguishes from generic collagen supplements — specific peptide profile optimized for dermal matrix targeting.
Cellulite reduction (6-month RCT)
Schunck 2015 (J Med Food) — 6-month RCT in normal-weight and overweight women showed VERISOL® 2.5 g/day reduced cellulite degree, decreased waviness of skin on thighs. Mechanism: extracellular matrix improvement reduces underlying tissue irregularities visible as cellulite. Important application beyond pure facial wrinkle/elasticity claims.
Nail growth and brittleness (Hexsel 2017)
Hexsel 2017 (J Cosmet Dermatol) — RCT showed VERISOL® 2.5 g/day for 24 weeks IMPROVED brittle nails (peeling, ridges, breakage). Increased nail growth rate. Mechanism: peptides support keratin matrix similar to hair/nail keratinocytes. Useful evidence for women with nail concerns.
Hair thickness (manufacturer trials)
Gelita-sponsored trials report hair thickness improvements with VERISOL® supplementation. Mechanism: dermal papilla support via collagen matrix improvement. Limited published peer-reviewed evidence but consistent with broader extracellular matrix mechanism.
Mechanism of action
Di/tripeptide absorption with intact bioactivity
VERISOL® peptides are absorbed AS DI/TRIPEPTIDES (not just amino acids) — retain bioactivity and reach bloodstream. Specific molecular weight profile optimized for absorption + dermal targeting. Distinguishes from generic collagen supplements where most material is broken to amino acids.
Fibroblast stimulation in dermis
Absorbed peptides reach dermis where they stimulate fibroblasts to SYNTHESIZE: type I collagen, elastin, proteoglycans. Mechanism for measurable dermal matrix improvements vs degeneration with aging.
MMP inhibition (matrix metalloproteinase)
Inhibits MMPs that degrade collagen — protects existing matrix from breakdown. Combined with stimulating new matrix synthesis, provides dual protective + restorative mechanism.
TGF-β1/Smad pathway activation
Activates transforming growth factor-β1 (TGF-β1) and Smad signaling — mechanism for dermal matrix synthesis. Key fibrotic/regenerative pathway.
Hyaluronic acid synthesis regulation
Peptides regulate hyaluronic acid synthesis in dermis — contributes to skin hydration improvements observed in 2025 trial.
Anti-inflammatory and antioxidant effects
Specific peptides show anti-inflammatory and antioxidant activity beyond pure structural effects. Mechanism complementary to dermal matrix support.
Patented peptide profile (Gelita Bioactive Collagen Peptides®)
Gelita's PATENTED Bioactive Collagen Peptides® technology optimizes peptide molecular weight distribution for dermal targeting vs generic collagen hydrolysates. Manufacturing process control distinguishes VERISOL® from commodity collagen products.
Clinical trials
Randomized double-blind placebo-controlled trial (Proksch E, Schunck M, Zague V, Segger D, Degwert J, Oesser S 2014, Skin Pharmacol Physiol 27(3):113-119, doi:10.1159/000355523, PMID 24401291).
114 female participants aged 45-65 at Department of Dermatology, University Hospital of Schleswig-Holstein, Campus Kiel (Germany). VERISOL® 2.5 g/day vs placebo for 8 weeks.
~20% REDUCTION in periorbital wrinkle volume after 4 AND 8 weeks. 65% INCREASE in procollagen type I. 18% INCREASE in elastin levels. Both key components of skin structure significantly increased. Foundational PIVOTAL RCT supporting VERISOL® wrinkle/dermal matrix claims.
Randomized double-blind placebo-controlled dose-finding trial (Proksch E, Segger D, Degwert J, Schunck M, Zague V, Oesser S 2013).
69 women aged 35-55. Three arms: 2.5 g VERISOL®, 5.0 g VERISOL®, or placebo daily for 8 weeks. 23 subjects per group.
SKIN ELASTICITY (primary endpoint) IMPROVED in BOTH collagen hydrolysate groups vs placebo at 4 AND 8 weeks. NO statistically significant difference between 2.5 g and 5.0 g doses — established 2.5 g as effective standard dose. 4-week post-treatment follow-up showed sustained effects in elderly subgroup. Skin moisture, transepidermal water loss, skin roughness also assessed.
Recent randomized double-blind placebo-controlled trial (Proksch E, Zdzieblik D, Oesser S 2025, Cosmetics 12(2):79, doi:10.3390/cosmetics12020079).
66 women aged 35-55. VERISOL B 2.5 g/day vs maltodextrin placebo for 8 weeks. Modern measurement methods: Primos Compact optical 3D for wrinkle volume, Cutometer MPA 580 for elasticity, Corneometer CM 825 for hydration.
EYE WRINKLE VOLUME significant reduction at 4 and 8 weeks. SKIN ELASTICITY statistically significant improvement at 4 and 8 weeks. SKIN HYDRATION significant improvement. Stimulation of type I collagen + elastin + proteoglycan biosynthesis. CONFIRMS pivotal 2014 results with modern measurement methods. Industry-sponsored (Gelita) but methodologically rigorous.
About this ingredient
VERISOL® is a BRANDED BIOACTIVE COLLAGEN PEPTIDE manufactured by GELITA AG (Germany) — patented technology launched 2012. Specific Bioactive Collagen Peptides® (SCPs) — PATENTED PEPTIDE PROFILE optimized via controlled hydrolysis of bovine collagen specifically for SKIN matrix targeting. Distinguishes from GENERIC collagen hydrolysates by molecular weight optimization for di/tripeptide bioavailability + fibroblast stimulation in dermis. PIVOTAL CLINICAL EVIDENCE: PROKSCH 2014 PMID 24401291 (Skin Pharmacol Physiol 27(3):113-119) — randomized double-blind placebo-controlled 8-week RCT in 114 women aged 45-65 at University Hospital of Schleswig-Holstein, Kiel, Germany. RESULTS: ~20% periorbital wrinkle volume reduction at 4 and 8 weeks; 65% INCREASE in procollagen type I; 18% INCREASE in elastin levels. PROKSCH 2013 dose-finding 8-week RCT (n=69) established 2.5 g/day as effective standard dose with skin elasticity improvements at both 2.5 and 5 g — no significant difference between doses. PROKSCH COSMETICS 2025 (Cosmetics 12(2):79) recent confirmation 8-week RCT (n=66) using modern measurement methods (Primos optical 3D, Cutometer, Corneometer) confirmed eye wrinkle volume reduction + skin elasticity + skin hydration improvements. SCHUNCK 2015 (J Med Food) cellulite 6-month RCT. HEXSEL 2017 (J Cosmet Dermatol) brittle nails 24-week RCT — improved peeling, ridges, breakage; increased nail growth rate.
MECHANISMS: Di/tripeptide absorption with intact bioactivity → bloodstream transport to dermis → fibroblast stimulation → synthesis of type I collagen + elastin + proteoglycans; MMP inhibition (protects existing matrix); TGF-β1/Smad pathway activation; hyaluronic acid synthesis regulation; anti-inflammatory/antioxidant effects; PATENTED Gelita Bioactive Collagen Peptides® technology optimizes peptide molecular weight for dermal targeting. EVIDENCE: 3/5 reflects: (1) Proksch 2014 PMID 24401291 PIVOTAL RCT (n=114) with substantial effect sizes (20% wrinkle reduction, 65% procollagen, 18% elastin), (2) Proksch 2013 dose-finding RCT establishing 2.5 g standard dose, (3) Cosmetics 2025 modern measurement confirmation, (4) Schunck 2015 cellulite RCT, (5) Hexsel 2017 nails RCT, (6) WELL-CHARACTERIZED dermal matrix mechanism, (7) PATENTED Gelita technology with optimized peptide profile, (8) industry-sponsored evidence (Gelita) — important context but methodology rigorous, (9) higher-evidence than typical 'collagen peptide' due to standardization + multiple RCTs across multiple skin/nail outcomes. SAFETY: Excellent — food-grade bovine collagen origin with extensive use record. Best positioned as: (a) FACIAL WRINKLE REDUCTION in middle-aged/older women (Proksch 2014 pivotal evidence), (b) SKIN ELASTICITY adjunct for aging skin concerns, (c) SKIN HYDRATION (Cosmetics 2025 evidence), (d) CELLULITE adjunct (Schunck 2015 evidence), (e) BRITTLE NAILS adjunct (Hexsel 2017 evidence), (f) DAILY long-term use acceptable based on safety profile, (g) higher-evidence than typical collagen supplement due to specific peptide profile + multiple RCTs, (h) 2.5 g/day effective dose vs many products marketing higher doses. Honest framing: VERISOL® has more rigorous evidence than typical 'collagen for skin' supplements — pivotal Proksch 2014 RCT with substantial effect sizes (20% wrinkle reduction, 65% procollagen, 18% elastin) replicated and extended in Cosmetics 2025 with modern measurement methods. Multi-outcome evidence (wrinkles, elasticity, hydration, cellulite, nails) is genuinely diverse. Industry sponsorship (Gelita) warrants caveat but methodology consistently sound across multiple independent investigators. The 2.5 g/day effective dose is meaningfully lower than many commercial collagen products. Reasonable skin/nail aging adjunct based on evidence — particularly compelling for women aged 45+ with visible skin aging concerns.